TP53 and cancer: Future investigations should focus on the selective regulation of p53 signaling, for instance, by employing cardiac-specific delivery systems or by targeting post-translational modifications, as such approaches may enable cardioprotection while maintaining the anti-cancer efficacy of doxorubicin.